ERBB2 and non-small cell lung carcinoma: These recommendations were based on a defined spectrum of molecular alterations that have well-known treatment options for NSCLC such as EGFR mutations, HER2 amplifications, MET exon 14 skipping or RET/ALK/ROS1 fusions (Fig. 4b).